Update on the Pathogenesis, Diagnosis, and Treatment of Neuromyelitis Optica Spectrum Disorder
Dean Wingerchuk, MD, MSc, FRCP(C)
Professor and Chair
Department of Neurology
This case-based enduring activity will cover the treatment and management of patients with NMOSD.
This activity is designed to meet the educational needs of US-based neurologists, neuro-ophthalmologists, and emergency physicians who treat patients with NMOSD.
After completing the CME activity, learners should be better able to:
- Describe dysfunctional immunologic factors, such as IL-6, and pathways of clinical importance for NMOSD therapy
- Discuss best practices for early diagnosis of NMOSD, including differential diagnosis and AQP4-IgG testing
- Review the mechanisms of action of emerging treatments for NMOSD and clinical trial data on their safety and efficacy profiles
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
This CME activity was planned and produced in accordance with the ACCME Essentials.
CREDIT DESIGNATION STATEMENT
Med Learning Group designates this web-based activity for a maximum of 1.0 AMA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
NURSING CREDIT INFORMATION
This program would be beneficial for nurses involved in the treatment and management of patients with HCC.
CNE Credits: 1.0 ANCC Contact Hour.
Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. Awarded 1.0 contact hours of continuing nursing education of RNs and APNs.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in a MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturers of any commercial products and/or providers of commercial services that are discussed in an educational activity.
DISCLOSURE OF FINANCIAL RELATIONSHIPS
Dean Wingerchuk, MD, MSc, FRCP(C) receives research support from Alexion and Terumo BCT and is a consultant for MedImmune, Novartis, Biogen, Celgene, Genentech, TG Therapeutics, Arcus Medica, Third Rock Ventures, and Reistone and serves on an adjudication committee for a neuromyelitis optica spectrum disorder (NMOSD) clinical trial (Viela Bio).
CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.
CNE Content Review
The content of this activity was peer-reviewed by a nurse reviewer.
The reviewer of this activity has nothing to disclose.
The staff, planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:
Matthew Frese, General Manager of Med Learning Group has nothing to disclose.
Christina Gallo, SVP, Educational Development of Med Learning Group has nothing to disclose.
Ashley Whitehurst, Program Manager of Med Learning Group has nothing to disclose.
Chris Drury, Medical Director of Med Learning Group has nothing to disclose.
Lauren Welch, MA, VP of Accreditation and Outcomes of Med Learning Group has nothing to disclose.
Russie Allen, Accreditation and Outcomes Coordinator of Med Learning Group has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
During this lecture, the faculty may mention the use of medications for both FDA-approved and nonapproved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CME credit for this enduring activity. To receive CME/CNE credit participants must:
1. Read the CME/CNE information and faculty disclosures;
2. Participate in the enduring activity; and
3. Complete pre-and-post surveys and evaluation.
You will receive your certificate as a downloadable file.
Med Learning Group makes every effort to develop CME activities that are science-based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making ability before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact Med Learning Group at firstname.lastname@example.org
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at http://medlearninggroup.com/privacy-policy/
RELEASE DATE: March 13, 2020
EXPIRATION DATE: March 13, 2021
Copyright © 2020 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.